{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T14:57:06Z","timestamp":1703084226693},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1111\/bjd.14378","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T23:53:28Z","timestamp":1455321208000},"page":"255-256","source":"Crossref","is-referenced-by-count":6,"title":["Time for a patient-oriented outcome in vitiligo: the vitiligo noticeability scale"],"prefix":"10.1093","volume":"174","author":[{"given":"K.","family":"Ezzedine","sequence":"first","affiliation":[{"name":"Department of Dermatology; Henri Mondor Hospital and EpiDermE; Universit\u00e9 Paris-Est Cr\u00e9teil Val-de-Marne; 94010 Cr\u00e9teil France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pandya","sequence":"additional","affiliation":[{"name":"Department of Dermatology; University of Texas Southwestern Medical Center; Dallas Texas U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"key":"10.1111\/bjd.14378-BIB0001|bjd14378-cit-0001","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"10.1111\/bjd.14378-BIB0002|bjd14378-cit-0002","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4103\/0253-7176.135385","article-title":"Psychiatric morbidity and quality of life in vitiligo patients","volume":"36","author":"Ramakrishna","year":"2014","journal-title":"Indian J Psychol Med"},{"key":"10.1111\/bjd.14378-BIB0003|bjd14378-cit-0003","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2133.2003.05097_9.x","article-title":"Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome","volume":"148","author":"Parsad","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14378-BIB0004|bjd14378-cit-0004","first-page":"CD003263","article-title":"Interventions for vitiligo","volume":"2","author":"Whitton","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/bjd.14378-BIB0005|bjd14378-cit-0005","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2133.2012.11056.x","article-title":"Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials","volume":"167","author":"Eleftheriadou","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14378-BIB0006|bjd14378-cit-0006","doi-asserted-by":"crossref","first-page":"223ra223","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1111\/bjd.14378-BIB0007|bjd14378-cit-0007","doi-asserted-by":"crossref","first-page":"174ra28","DOI":"10.1126\/scitranslmed.3005127","article-title":"Mutant HSP70 reverses autoimmune depigmentation in vitiligo","volume":"5","author":"Mosenson","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1111\/bjd.14378-BIB0008|bjd14378-cit-0008","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/jid.2011.321","article-title":"Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis","volume":"132","author":"Spritz","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14378-BIB0009|bjd14378-cit-0009","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/pcmr.12354","article-title":"Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus","volume":"28","author":"Eleftheriadou","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1111\/bjd.14378-BIB0010|bjd14378-cit-0010","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjd.14208","article-title":"Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success","volume":"174","author":"Batchelor","year":"2016","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.14378","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.14378","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.14378\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:18:42Z","timestamp":1676384322000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/174\/2\/255\/6616623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.14378","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}